General Information - Stages of the Move


Dear colleague, 

First of all, we would like to express our sincere apologies for the delays you have experienced in receiving your test results in recent weeks. We understand how uncomfortable this can be for you, your patients and the colleagues you work with.

As you know, our laboratory is currently in the process of moving to our new premises in Frépillon. This is the biggest move we have ever undertaken in the world of biology, with more than 600 machines to be moved and requalified, while maintaining the continuity of our care activities.

In addition, we would like to inform you that we are also experiencing delivery delays and/or shortages of reagents and consumables from our suppliers due to both the international economic situation and the application of the new European IVDR regulation. Despite our efforts to anticipate these disruptions, some deliveries may be delayed, which may affect our ability to complete your analyses within the usual timescales. We are working closely with our suppliers to resolve these issues as quickly as possible and minimise the impact on our services.

We recognise that this can be a difficult time for you, but we want to assure you that we will do our utmost to ensure that your tests are completed on time.
We understand that this can be a difficult time for you, but we want to assure you that we are doing everything we can to minimise disruption and return to normal operations as soon as possible. We are currently half way through our move and we are confident that the results will be well worth the effort.

Our new premises will be equipped with cutting-edge technology that will enable us to improve the quality, tracability and turnaround times of our examinations. Among these innovations, our tube sorting and conveying chain and our automatic, connected 4°C and -20°C temperature chambers will play a key role in our ability to meet your needs and those of your patients.

During this period of transition, we would also like to inform you that we are communicating regularly via our newsletter and on your My Cerba accounts. We will keep you informed once or twice a week of the examinations affected by the move and those likely to be delayed. We hope that this information will enable you to better plan your activities and manage your patients' expectations.

We would like to thank you sincerely for your understanding and patience during this period of transition. We remain at your disposal to answer any questions or concerns you may have.

Yours sincerely
Aurélie Driss-Corbin 
CEO Cerba